Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. With a market cap of $12 billion, Bio-Techne operates through Protein Sciences, and Diagnostics and Genomics segments.

The biotech major is expected to announce second-quarter results on Thursday, Feb. 6. Ahead of the event analysts expect Bio-Techne to report a non-GAAP profit of $0.33 per share, the same as the $0.33 per share reported in the year-ago quarter. While the company has surpassed Wall Street’s bottom-line expectation thrice over the past four quarters, it has missed the estimates on one other occasion. Its adjusted EPS of the last reported quarter increased 5.7% year-over-year to $0.37 exceeding analysts' estimates by 8.8%.

For fiscal 2025, Bio-Techne is expected to deliver an adjusted EPS of $1.68, up 7% from $1.57 in fiscal 2024. While in fiscal 2026, its earnings are expected to surge 20.2% year-over-year to $2.02 per share.

TECH stock prices have gained 8.6% over the past 52 weeks, lagging behind the S&P 500 Index’s ($SPX) 26.5% surge but outperforming the Healthcare Select Sector SPDR Fund’s (XLV) marginal gains during the same time frame.

Bio-Techne stock price soared 7.5% after the release of its better-than-expected Q1 results on Oct. 30. The company reported a robust 4.5% year-over-year growth in net sales to $289.5 million, outpacing Wall Street’s topline expectations by a notable 3.1%. The topline growth was primarily driven by the continued adoption and utilization across the Diagnostics & Spatial Biology (DSS) segment, leading to a staggering 14.3% year-over-year growth in segment revenue to $83.2 million. Meanwhile, Bio-Techne’s earnings also surpassed analysts’ bottom-line estimates by a significant margin.

Analysts remain strongly bullish on the stock’s prospects. Bio-Techne has a consensus “Strong Buy” rating overall. Out of the 13 analysts covering the stock, 10 recommend “Strong Buy” and three suggest a “Hold” rating. Its mean price target of $85 indicates a 12.1% premium to current price levels.